ArticleScientific reports2025
Impact of smoking and opium cessation on gastrointestinal cancer risk: A 15-year longitudinal study in Golestan Cohort.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smoking and opium use are risk factors for gastrointestinal cancers, yet the extent to which cessation reduces cancer risk remains unclear, particularly in non-Western populations. This study analyzed data from the Golestan Cohort Study in northeastern Iran, comprising 50,045 adults aged 40-75 years followed for a median of 15 years. Participants were classified into never-users, current smokers or recent quitters (less than 5 years), and long-term quitters (more than 5 years). For esophageal cancer, long-term quitters demonstrated substantial risk reductions (HR for smoking: 0.68; 95% CI: 0.47-0.99; HR for opium: 0.33; 95% CI: 0.12-0.90), while current users and recent quitters of both smoking and opium indicated increased risks (HR for smoking: 1.53; 95% CI: 1.14-2.07; HR for opium: 1.50; 95% CI: 1.20-1.88). For stomach cancer, long-term smoking quitters showed a protective effect, with a 35% risk reduction though no significant risk reduction was observed for long-term opium cessation. For pancreatic cancer no significant risk reduction was noted among long-term quitters. This study highlights that cessation of smoking or opium use for more than 5 years can reduce the risk of esophageal cancer, while risk reduction for other types of gastrointestinal cancers requires longer cessation duration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.